3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Neoplasms
4
Venous Thrombosis
2
Venous Thromboembolism
2
Colonic Neoplasms
2
Carcinoma, Hepatocellular
2
Thrombosis
1
Thromboembolism
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Multiple Myeloma
1
Lung Neoplasms
1
Inflammation
1
Immune System Diseases
1
Glioma
1
Gastrointestinal Stromal Tumors
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Dyskinesias
1
Duodenal Neoplasms
1
Cholangiocarcinoma
1
Cardiovascular Diseases
1
Breast Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
Docetaxel
21
Radiosurgery
20
Radiotherapy
17
Androgen Antagonists
14
Leuprolide
12
Goserelin
12
bicalutamide
11
Prednisone
9
Gonadotropin-Releasing Hormone
9
Abiraterone Acetate
9
enzalutamide
8
Surveys and Questionnaires
8
Radiotherapy, Intensity-Modulated
8
Brachytherapy
8
Blood Specimen Collection
8
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
7
Triptorelin Pamoate
7
Multiparametric Magnetic Resonance Imaging
7
abiraterone
5
pembrolizumab
4
cabazitaxel
4
Standard of Care
4
Positron Emission Tomography Computed Tomography
4
Metformin
4
Heavy Ion Radiotherapy
4
Flutamide
4
Exercise
4
Estramustine
4
luprolide acetate gel depot
3
darolutamide
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Prostatic Neoplasms
×
Rivaroxaban
×
Clear all
NCT06065592
2023-10-06
CAT_PB
Lebanese University
Phase 1
Unknown
500 enrolled